Summary
Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hyertensives. We examined the hemodynamic effects of ketanserin during long-term treatment in patients with heart failure. Five male patients with coronary artery disease and heart failure (NYHA classes II–III) were treated with ketanserin (80 mg daily) for 12 months. Before treatment, after 4 weeks, and after 12 months treatment, a Swan-Ganz catheter was placed into the pulmonary artery and pulmonary wedge pressure, cardiac output, mean arterial pressure, and heart rate were measured at rest and on exertion. The pulmonary wedge pressure at rest decreased from 8 mmHg before to 6 mmHg after 4 weeks and 12 months treatment; on exertion, it decreased from 31 mmHg before treatment to 24 mmHg after 4 weeks treatment and to 21 mmHg after 12 months treatment. The mean arterial pressure also decreased at rest and on exertion after 4 weeks treatment as well as after 12 months treatment. Cardiac output increased slightly and heart rate was unaltered. No serious side effects occurred. Ketanserin could become an alternative vasodilator drug in the treatment of patients with heart failure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Braunwald E, Sonnenblick EH, et al., eds. Heart Failure. New York: Raven Press, 1984:1–13.
Cohn JN, ed. Drug Treatment of Heart Failure. New York: Yorke Medical Books, 1983:1–12.
Vanhoutte PM, Cohen RA. The elusory role of serotonin in vascular function and disease. Biochem Pharmacol 1983 ;32:3671–3674.
Leysen JE, Awonters F, Kennis L, et al. Receptor binding profile of R 41468, a novel antagonist at 5 HT2 receptors. Life Sci 1981;28:1015–1022.
Van Neuten JM, Janssens WJ. Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: Inhibition by ketanserin. Hypertension 1986;4:55–59.
Demoulin JC, Bertholet M, Soumagne D, et al. 5 HT2-receptor blockade in the treatment of heart failure. Lancet 1981;1186–1188.
De Clerk F, Herman AG. 5-Hydroxytryptamine and platelet aggregation. Fed Proc 1983;42:228–232.
Vanhoutte P, Amery A, Birkenhäger W, et al. Serotoninergic mechanisms in hypertension. Hypertension 1988;11: 111–133.
Wenting GJ, Woittiez AJJ, Man In't Veld AJ, et al. 5-HT, alpha-adrenoceptors and blood pressure. Hypertension 1984; 6:100–109.
Andersson A, Morgan T, Dumpys R. The effect of ketanserin in essential hypertension. Clin Exp Pharmacol Physiol 1983;10:331–333.
Waal-Manning HJ, Brown SA, Spears GF, et al. Clinical studies with ketanserin in hypertension. J Cardiovasc Pharmacol 1985;7:154–158.
Brune S, Neuhaus KL, Kreuzer H. Akute und chronische hämodynamische Wirkung von Ketanserin bei patienten mit koronarer Herzkrankheit. Corvas 1988;5/6:229–233.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brune, S., Schmidt, T., Tebbe, U. et al. Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure. Cardiovasc Drug Ther 4, 85–87 (1990). https://doi.org/10.1007/BF00053434
Issue Date:
DOI: https://doi.org/10.1007/BF00053434